nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—ABCB1—Lisinopril—dilated cardiomyopathy	0.321	0.532	CbGbCtD
Naltrexone—ABCB1—Spironolactone—dilated cardiomyopathy	0.282	0.468	CbGbCtD
Naltrexone—Pancreatitis acute—Furosemide—dilated cardiomyopathy	0.0098	0.0271	CcSEcCtD
Naltrexone—Ulcer—Spironolactone—dilated cardiomyopathy	0.00879	0.0243	CcSEcCtD
Naltrexone—Appetite absent—Lisinopril—dilated cardiomyopathy	0.00682	0.0189	CcSEcCtD
Naltrexone—Lethargy—Spironolactone—dilated cardiomyopathy	0.00616	0.017	CcSEcCtD
Naltrexone—Injection site pain—Furosemide—dilated cardiomyopathy	0.00554	0.0153	CcSEcCtD
Naltrexone—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00544	0.015	CcSEcCtD
Naltrexone—Disturbance in attention—Furosemide—dilated cardiomyopathy	0.00522	0.0145	CcSEcCtD
Naltrexone—Throat sore—Lisinopril—dilated cardiomyopathy	0.00471	0.013	CcSEcCtD
Naltrexone—Laryngitis—Lisinopril—dilated cardiomyopathy	0.00471	0.013	CcSEcCtD
Naltrexone—Oropharyngeal discomfort—Lisinopril—dilated cardiomyopathy	0.00467	0.0129	CcSEcCtD
Naltrexone—Rhinorrhoea—Lisinopril—dilated cardiomyopathy	0.00419	0.0116	CcSEcCtD
Naltrexone—Mental disability—Furosemide—dilated cardiomyopathy	0.00393	0.0109	CcSEcCtD
Naltrexone—Chest discomfort—Lisinopril—dilated cardiomyopathy	0.00384	0.0106	CcSEcCtD
Naltrexone—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.00373	0.0103	CcSEcCtD
Naltrexone—Swelling—Furosemide—dilated cardiomyopathy	0.00372	0.0103	CcSEcCtD
Naltrexone—Alopecia—Spironolactone—dilated cardiomyopathy	0.00369	0.0102	CcSEcCtD
Naltrexone—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00349	0.00967	CcSEcCtD
Naltrexone—Thirst—Furosemide—dilated cardiomyopathy	0.00345	0.00955	CcSEcCtD
Naltrexone—Purpura—Furosemide—dilated cardiomyopathy	0.00341	0.00943	CcSEcCtD
Naltrexone—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00339	0.00939	CcSEcCtD
Naltrexone—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00337	0.00933	CcSEcCtD
Naltrexone—Lethargy—Furosemide—dilated cardiomyopathy	0.00335	0.00927	CcSEcCtD
Naltrexone—Malaise—Spironolactone—dilated cardiomyopathy	0.00328	0.00907	CcSEcCtD
Naltrexone—Irritability—Furosemide—dilated cardiomyopathy	0.00313	0.00867	CcSEcCtD
Naltrexone—Discomfort—Spironolactone—dilated cardiomyopathy	0.00306	0.00846	CcSEcCtD
Naltrexone—Dehydration—Furosemide—dilated cardiomyopathy	0.00305	0.00845	CcSEcCtD
Naltrexone—Confusional state—Spironolactone—dilated cardiomyopathy	0.00299	0.00828	CcSEcCtD
Naltrexone—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00297	0.00821	CcSEcCtD
Naltrexone—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00296	0.00818	CcSEcCtD
Naltrexone—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00285	0.00788	CcSEcCtD
Naltrexone—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00278	0.00769	CcSEcCtD
Naltrexone—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.0027	0.00749	CcSEcCtD
Naltrexone—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00266	0.00735	CcSEcCtD
Naltrexone—Somnolence—Spironolactone—dilated cardiomyopathy	0.00264	0.0073	CcSEcCtD
Naltrexone—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.0026	0.0072	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00256	0.00709	CcSEcCtD
Naltrexone—Arthritis—Lisinopril—dilated cardiomyopathy	0.00254	0.00702	CcSEcCtD
Naltrexone—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00246	0.00682	CcSEcCtD
Naltrexone—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00244	0.00677	CcSEcCtD
Naltrexone—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00244	0.00677	CcSEcCtD
Naltrexone—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00239	0.00662	CcSEcCtD
Naltrexone—Face oedema—Lisinopril—dilated cardiomyopathy	0.00238	0.00658	CcSEcCtD
Naltrexone—Urticaria—Spironolactone—dilated cardiomyopathy	0.00236	0.00652	CcSEcCtD
Naltrexone—Irritability—Lisinopril—dilated cardiomyopathy	0.00235	0.00651	CcSEcCtD
Naltrexone—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00235	0.00649	CcSEcCtD
Naltrexone—Dehydration—Lisinopril—dilated cardiomyopathy	0.00229	0.00634	CcSEcCtD
Naltrexone—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00222	0.00614	CcSEcCtD
Naltrexone—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.0022	0.0061	CcSEcCtD
Naltrexone—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00219	0.00605	CcSEcCtD
Naltrexone—Influenza—Lisinopril—dilated cardiomyopathy	0.00213	0.00589	CcSEcCtD
Naltrexone—Eye disorder—Furosemide—dilated cardiomyopathy	0.00212	0.00588	CcSEcCtD
Naltrexone—Tinnitus—Furosemide—dilated cardiomyopathy	0.00212	0.00586	CcSEcCtD
Naltrexone—Pruritus—Spironolactone—dilated cardiomyopathy	0.0021	0.00581	CcSEcCtD
Naltrexone—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00207	0.00574	CcSEcCtD
Naltrexone—Sweating increased—Lisinopril—dilated cardiomyopathy	0.00207	0.00574	CcSEcCtD
Naltrexone—Angiopathy—Furosemide—dilated cardiomyopathy	0.00206	0.0057	CcSEcCtD
Naltrexone—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00205	0.00568	CcSEcCtD
Naltrexone—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00205	0.00567	CcSEcCtD
Naltrexone—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00203	0.00562	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00198	0.00548	CcSEcCtD
Naltrexone—Malnutrition—Furosemide—dilated cardiomyopathy	0.00198	0.00547	CcSEcCtD
Naltrexone—Dizziness—Spironolactone—dilated cardiomyopathy	0.00196	0.00543	CcSEcCtD
Naltrexone—Flatulence—Furosemide—dilated cardiomyopathy	0.00195	0.00539	CcSEcCtD
Naltrexone—Weight increased—Lisinopril—dilated cardiomyopathy	0.00194	0.00536	CcSEcCtD
Naltrexone—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00194	0.00536	CcSEcCtD
Naltrexone—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00193	0.00533	CcSEcCtD
Naltrexone—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00191	0.00529	CcSEcCtD
Naltrexone—Muscle spasms—Furosemide—dilated cardiomyopathy	0.0019	0.00526	CcSEcCtD
Naltrexone—Depression—Lisinopril—dilated cardiomyopathy	0.00189	0.00524	CcSEcCtD
Naltrexone—Vomiting—Spironolactone—dilated cardiomyopathy	0.00189	0.00522	CcSEcCtD
Naltrexone—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00187	0.00518	CcSEcCtD
Naltrexone—Rash—Spironolactone—dilated cardiomyopathy	0.00187	0.00518	CcSEcCtD
Naltrexone—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00187	0.00517	CcSEcCtD
Naltrexone—Vision blurred—Furosemide—dilated cardiomyopathy	0.00186	0.00516	CcSEcCtD
Naltrexone—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00186	0.00515	CcSEcCtD
Naltrexone—Headache—Spironolactone—dilated cardiomyopathy	0.00186	0.00514	CcSEcCtD
Naltrexone—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00185	0.00511	CcSEcCtD
Naltrexone—Agitation—Furosemide—dilated cardiomyopathy	0.00182	0.00503	CcSEcCtD
Naltrexone—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.0018	0.00497	CcSEcCtD
Naltrexone—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00179	0.00496	CcSEcCtD
Naltrexone—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00178	0.00493	CcSEcCtD
Naltrexone—Nausea—Spironolactone—dilated cardiomyopathy	0.00176	0.00488	CcSEcCtD
Naltrexone—Hepatitis—Lisinopril—dilated cardiomyopathy	0.0017	0.00472	CcSEcCtD
Naltrexone—Hallucination—Lisinopril—dilated cardiomyopathy	0.0017	0.00469	CcSEcCtD
Naltrexone—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00169	0.00468	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00167	0.00463	CcSEcCtD
Naltrexone—Dry mouth—Furosemide—dilated cardiomyopathy	0.00165	0.00456	CcSEcCtD
Naltrexone—Confusional state—Furosemide—dilated cardiomyopathy	0.00163	0.0045	CcSEcCtD
Naltrexone—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00161	0.00447	CcSEcCtD
Naltrexone—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00159	0.0044	CcSEcCtD
Naltrexone—Shock—Furosemide—dilated cardiomyopathy	0.00159	0.00439	CcSEcCtD
Naltrexone—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00158	0.00438	CcSEcCtD
Naltrexone—Skin disorder—Furosemide—dilated cardiomyopathy	0.00157	0.00434	CcSEcCtD
Naltrexone—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00156	0.00432	CcSEcCtD
Naltrexone—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00155	0.00428	CcSEcCtD
Naltrexone—Anorexia—Furosemide—dilated cardiomyopathy	0.00154	0.00426	CcSEcCtD
Naltrexone—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00154	0.00425	CcSEcCtD
Naltrexone—Chills—Lisinopril—dilated cardiomyopathy	0.00153	0.00423	CcSEcCtD
Naltrexone—Alopecia—Lisinopril—dilated cardiomyopathy	0.00151	0.00417	CcSEcCtD
Naltrexone—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00149	0.00413	CcSEcCtD
Naltrexone—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00148	0.00411	CcSEcCtD
Naltrexone—Flatulence—Lisinopril—dilated cardiomyopathy	0.00146	0.00405	CcSEcCtD
Naltrexone—Tension—Lisinopril—dilated cardiomyopathy	0.00146	0.00403	CcSEcCtD
Naltrexone—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00145	0.00402	CcSEcCtD
Naltrexone—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00145	0.00401	CcSEcCtD
Naltrexone—Nervousness—Lisinopril—dilated cardiomyopathy	0.00144	0.00399	CcSEcCtD
Naltrexone—Back pain—Lisinopril—dilated cardiomyopathy	0.00144	0.00397	CcSEcCtD
Naltrexone—Somnolence—Furosemide—dilated cardiomyopathy	0.00143	0.00397	CcSEcCtD
Naltrexone—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00143	0.00395	CcSEcCtD
Naltrexone—Decreased appetite—Furosemide—dilated cardiomyopathy	0.0014	0.00388	CcSEcCtD
Naltrexone—Vision blurred—Lisinopril—dilated cardiomyopathy	0.0014	0.00387	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00139	0.00386	CcSEcCtD
Naltrexone—Fatigue—Furosemide—dilated cardiomyopathy	0.00139	0.00385	CcSEcCtD
Naltrexone—Tremor—Lisinopril—dilated cardiomyopathy	0.00139	0.00385	CcSEcCtD
Naltrexone—Constipation—Furosemide—dilated cardiomyopathy	0.00138	0.00382	CcSEcCtD
Naltrexone—Pain—Furosemide—dilated cardiomyopathy	0.00138	0.00382	CcSEcCtD
Naltrexone—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00138	0.00381	CcSEcCtD
Naltrexone—Angioedema—Lisinopril—dilated cardiomyopathy	0.00136	0.00375	CcSEcCtD
Naltrexone—Malaise—Lisinopril—dilated cardiomyopathy	0.00134	0.0037	CcSEcCtD
Naltrexone—Syncope—Lisinopril—dilated cardiomyopathy	0.00133	0.00368	CcSEcCtD
Naltrexone—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00133	0.00368	CcSEcCtD
Naltrexone—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00132	0.00365	CcSEcCtD
Naltrexone—Palpitations—Lisinopril—dilated cardiomyopathy	0.00131	0.00363	CcSEcCtD
Naltrexone—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.0013	0.00361	CcSEcCtD
Naltrexone—Cough—Lisinopril—dilated cardiomyopathy	0.00129	0.00358	CcSEcCtD
Naltrexone—Urticaria—Furosemide—dilated cardiomyopathy	0.00128	0.00355	CcSEcCtD
Naltrexone—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00128	0.00353	CcSEcCtD
Naltrexone—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00128	0.00353	CcSEcCtD
Naltrexone—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00126	0.0035	CcSEcCtD
Naltrexone—Chest pain—Lisinopril—dilated cardiomyopathy	0.00126	0.0035	CcSEcCtD
Naltrexone—Myalgia—Lisinopril—dilated cardiomyopathy	0.00126	0.0035	CcSEcCtD
Naltrexone—Anxiety—Lisinopril—dilated cardiomyopathy	0.00126	0.00348	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00125	0.00347	CcSEcCtD
Naltrexone—Discomfort—Lisinopril—dilated cardiomyopathy	0.00125	0.00345	CcSEcCtD
Naltrexone—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00124	0.00342	CcSEcCtD
Naltrexone—Confusional state—Lisinopril—dilated cardiomyopathy	0.00122	0.00338	CcSEcCtD
Naltrexone—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00121	0.00335	CcSEcCtD
Naltrexone—Oedema—Lisinopril—dilated cardiomyopathy	0.00121	0.00335	CcSEcCtD
Naltrexone—Infection—Lisinopril—dilated cardiomyopathy	0.0012	0.00333	CcSEcCtD
Naltrexone—Shock—Lisinopril—dilated cardiomyopathy	0.00119	0.0033	CcSEcCtD
Naltrexone—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00119	0.00329	CcSEcCtD
Naltrexone—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00118	0.00327	CcSEcCtD
Naltrexone—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00118	0.00326	CcSEcCtD
Naltrexone—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00117	0.00324	CcSEcCtD
Naltrexone—Asthenia—Furosemide—dilated cardiomyopathy	0.00116	0.0032	CcSEcCtD
Naltrexone—Anorexia—Lisinopril—dilated cardiomyopathy	0.00115	0.00319	CcSEcCtD
Naltrexone—Pruritus—Furosemide—dilated cardiomyopathy	0.00114	0.00316	CcSEcCtD
Naltrexone—Diarrhoea—Furosemide—dilated cardiomyopathy	0.0011	0.00306	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.0011	0.00305	CcSEcCtD
Naltrexone—Insomnia—Lisinopril—dilated cardiomyopathy	0.0011	0.00303	CcSEcCtD
Naltrexone—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00109	0.00301	CcSEcCtD
Naltrexone—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00108	0.00299	CcSEcCtD
Naltrexone—Somnolence—Lisinopril—dilated cardiomyopathy	0.00108	0.00298	CcSEcCtD
Naltrexone—Dizziness—Furosemide—dilated cardiomyopathy	0.00107	0.00295	CcSEcCtD
Naltrexone—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00105	0.00291	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00105	0.00289	CcSEcCtD
Naltrexone—Fatigue—Lisinopril—dilated cardiomyopathy	0.00104	0.00289	CcSEcCtD
Naltrexone—Constipation—Lisinopril—dilated cardiomyopathy	0.00104	0.00287	CcSEcCtD
Naltrexone—Pain—Lisinopril—dilated cardiomyopathy	0.00104	0.00287	CcSEcCtD
Naltrexone—Vomiting—Furosemide—dilated cardiomyopathy	0.00103	0.00284	CcSEcCtD
Naltrexone—Rash—Furosemide—dilated cardiomyopathy	0.00102	0.00282	CcSEcCtD
Naltrexone—Dermatitis—Furosemide—dilated cardiomyopathy	0.00102	0.00281	CcSEcCtD
Naltrexone—Headache—Furosemide—dilated cardiomyopathy	0.00101	0.0028	CcSEcCtD
Naltrexone—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000998	0.00276	CcSEcCtD
Naltrexone—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00099	0.00274	CcSEcCtD
Naltrexone—Urticaria—Lisinopril—dilated cardiomyopathy	0.000962	0.00266	CcSEcCtD
Naltrexone—Nausea—Furosemide—dilated cardiomyopathy	0.000959	0.00265	CcSEcCtD
Naltrexone—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000957	0.00265	CcSEcCtD
Naltrexone—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000957	0.00265	CcSEcCtD
Naltrexone—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000892	0.00247	CcSEcCtD
Naltrexone—Asthenia—Lisinopril—dilated cardiomyopathy	0.000869	0.0024	CcSEcCtD
Naltrexone—ABCB1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.000869	0.0245	CbGpPWpGaD
Naltrexone—Pruritus—Lisinopril—dilated cardiomyopathy	0.000857	0.00237	CcSEcCtD
Naltrexone—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000829	0.00229	CcSEcCtD
Naltrexone—OPRD1—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.000816	0.023	CbGpPWpGaD
Naltrexone—Dizziness—Lisinopril—dilated cardiomyopathy	0.000801	0.00222	CcSEcCtD
Naltrexone—Vomiting—Lisinopril—dilated cardiomyopathy	0.00077	0.00213	CcSEcCtD
Naltrexone—Rash—Lisinopril—dilated cardiomyopathy	0.000764	0.00211	CcSEcCtD
Naltrexone—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000763	0.00211	CcSEcCtD
Naltrexone—Headache—Lisinopril—dilated cardiomyopathy	0.000759	0.0021	CcSEcCtD
Naltrexone—OPRD1—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.000758	0.0214	CbGpPWpGaD
Naltrexone—Nausea—Lisinopril—dilated cardiomyopathy	0.000719	0.00199	CcSEcCtD
Naltrexone—OPRK1—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.000715	0.0202	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.000715	0.0202	CbGpPWpGaD
Naltrexone—OPRK1—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.000665	0.0187	CbGpPWpGaD
Naltrexone—OPRD1—Peptide GPCRs—AGTR1—dilated cardiomyopathy	0.000627	0.0177	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.000627	0.0177	CbGpPWpGaD
Naltrexone—OPRM1—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.000604	0.017	CbGpPWpGaD
Naltrexone—OPRM1—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.000562	0.0158	CbGpPWpGaD
Naltrexone—OPRK1—Peptide GPCRs—AGTR1—dilated cardiomyopathy	0.00055	0.0155	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00053	0.0149	CbGpPWpGaD
Naltrexone—OPRM1—Peptide GPCRs—AGTR1—dilated cardiomyopathy	0.000465	0.0131	CbGpPWpGaD
Naltrexone—OPRM1—IL4-mediated signaling events—IL10—dilated cardiomyopathy	0.000449	0.0126	CbGpPWpGaD
Naltrexone—OPRM1—IL4-mediated signaling events—RPS6KB1—dilated cardiomyopathy	0.000436	0.0123	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.000384	0.0108	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.000384	0.0108	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.000357	0.01	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.000336	0.00948	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.000336	0.00948	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.000324	0.00912	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.000324	0.00912	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.000313	0.00881	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.000301	0.00848	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.0003	0.00846	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—FAS—dilated cardiomyopathy	0.000299	0.00841	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.000295	0.00831	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.000284	0.00801	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.000284	0.00801	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.000284	0.008	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.000284	0.008	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000279	0.00787	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00027	0.00762	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.000264	0.00745	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.000264	0.00743	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000263	0.00742	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.000259	0.00729	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000257	0.00725	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000257	0.00725	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000246	0.00693	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000245	0.0069	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.00024	0.00676	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.00024	0.00676	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000239	0.00674	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000237	0.00668	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000233	0.00656	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000232	0.00653	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000231	0.00651	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000226	0.00636	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000226	0.00636	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.000223	0.00628	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000223	0.00627	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000222	0.00625	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000219	0.00617	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.000219	0.00616	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00021	0.00591	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.000208	0.00585	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000207	0.00583	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000207	0.00583	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000203	0.00572	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000202	0.00571	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.0002	0.00565	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000198	0.00558	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000196	0.00552	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000196	0.00552	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—RAF1—dilated cardiomyopathy	0.000194	0.00547	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000192	0.00541	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000191	0.00537	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000191	0.00537	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000188	0.00529	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000182	0.00513	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.000182	0.00513	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000177	0.005	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000176	0.00497	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000175	0.00493	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000173	0.00489	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	0.000173	0.00489	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000172	0.00484	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000172	0.00484	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000172	0.00484	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000171	0.00482	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000165	0.00464	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000162	0.00457	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000161	0.00454	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00016	0.0045	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000155	0.00438	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000155	0.00436	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.000154	0.00433	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000154	0.00433	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000151	0.00425	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000147	0.00413	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000145	0.00409	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000145	0.00409	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000144	0.00405	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000143	0.00403	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000139	0.00392	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000139	0.00392	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—TAZ—dilated cardiomyopathy	0.000135	0.00381	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000135	0.0038	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000132	0.00372	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000131	0.00368	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.00013	0.00366	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000125	0.00353	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—SDHA—dilated cardiomyopathy	0.000122	0.00345	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000122	0.00344	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000112	0.00315	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000111	0.00312	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000111	0.00312	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000106	0.00299	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000106	0.00298	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000103	0.00291	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000103	0.0029	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000101	0.00283	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000101	0.00283	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.0001	0.00283	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	9.97e-05	0.00281	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	9.76e-05	0.00275	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	9.76e-05	0.00275	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	9.71e-05	0.00274	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	9.71e-05	0.00274	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	9.35e-05	0.00263	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—AGT—dilated cardiomyopathy	9.3e-05	0.00262	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	9.08e-05	0.00256	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	9.05e-05	0.00255	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	9.03e-05	0.00254	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	8.82e-05	0.00248	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	8.82e-05	0.00248	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	8.74e-05	0.00246	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	8.51e-05	0.0024	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	8.2e-05	0.00231	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	8.2e-05	0.00231	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	8.2e-05	0.00231	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	8.08e-05	0.00228	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	7.95e-05	0.00224	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	7.94e-05	0.00224	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—AGT—dilated cardiomyopathy	7.86e-05	0.00221	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	7.73e-05	0.00218	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	7.67e-05	0.00216	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	7.63e-05	0.00215	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	7.52e-05	0.00212	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	7.47e-05	0.0021	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	7.45e-05	0.0021	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	7.45e-05	0.0021	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	7.39e-05	0.00208	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	7.33e-05	0.00207	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	7.08e-05	0.002	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	6.93e-05	0.00195	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	6.78e-05	0.00191	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	6.71e-05	0.00189	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PSEN2—dilated cardiomyopathy	6.69e-05	0.00189	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	6.6e-05	0.00186	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	6.6e-05	0.00186	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	6.43e-05	0.00181	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	6.31e-05	0.00178	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	6.27e-05	0.00177	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	6.2e-05	0.00175	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AGT—dilated cardiomyopathy	5.99e-05	0.00169	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	5.99e-05	0.00169	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.94e-05	0.00167	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.94e-05	0.00167	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.87e-05	0.00165	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	5.73e-05	0.00161	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—RAC1—dilated cardiomyopathy	5.69e-05	0.0016	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	5.61e-05	0.00158	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.52e-05	0.00156	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	5.5e-05	0.00155	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AGT—dilated cardiomyopathy	5.44e-05	0.00153	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	5.44e-05	0.00153	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.35e-05	0.00151	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AGT—dilated cardiomyopathy	5.25e-05	0.00148	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.21e-05	0.00147	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.21e-05	0.00147	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—RAC1—dilated cardiomyopathy	4.99e-05	0.00141	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	4.99e-05	0.00141	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.96e-05	0.0014	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.84e-05	0.00136	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AGT—dilated cardiomyopathy	4.77e-05	0.00134	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.69e-05	0.00132	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	4.65e-05	0.00131	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.57e-05	0.00129	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AGT—dilated cardiomyopathy	4.44e-05	0.00125	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.4e-05	0.00124	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.4e-05	0.00124	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.33e-05	0.00122	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—RAC1—dilated cardiomyopathy	4.22e-05	0.00119	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.09e-05	0.00115	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AGT—dilated cardiomyopathy	4.03e-05	0.00114	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AGTR1—dilated cardiomyopathy	4e-05	0.00113	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.96e-05	0.00112	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.8e-05	0.00107	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.78e-05	0.00106	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.72e-05	0.00105	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	3.42e-05	0.000964	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.38e-05	0.000954	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RAC1—dilated cardiomyopathy	3.36e-05	0.000948	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GPX1—dilated cardiomyopathy	3.32e-05	0.000936	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.31e-05	0.000933	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.26e-05	0.00092	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	3.26e-05	0.000918	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CD36—dilated cardiomyopathy	3.24e-05	0.000912	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AGT—dilated cardiomyopathy	3.21e-05	0.000906	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.21e-05	0.000905	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.95e-05	0.000831	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AGT—dilated cardiomyopathy	2.91e-05	0.000821	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AGT—dilated cardiomyopathy	2.82e-05	0.000794	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.8e-05	0.000789	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.76e-05	0.000778	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.59e-05	0.00073	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.49e-05	0.000702	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AGT—dilated cardiomyopathy	2.38e-05	0.000671	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.27e-05	0.00064	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RAF1—dilated cardiomyopathy	2.23e-05	0.000629	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.98e-05	0.000558	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.96e-05	0.000551	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.92e-05	0.000541	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.65e-05	0.000466	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.53e-05	0.000431	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	1.52e-05	0.000429	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CD36—dilated cardiomyopathy	1.48e-05	0.000418	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.34e-05	0.000378	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AGT—dilated cardiomyopathy	1.34e-05	0.000377	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.13e-05	0.000319	CbGpPWpGaD
